GlassScriptPhysician profile
Federico Del Toro
NPI 1932118445
$5,703.07
in general payments reported to CMS, 2019-2025
31 companies · $634 in 2025
The $634 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $793 · 2020: $308 · 2021: $1,028 · 2022: $1,052 · 2023: $1,179 · 2024: $708 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,521.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $823.75 | 2019-2025 | Veltassa, Korsuva |
| Amgen INC. | $647.29 | 2019-2025 | Tavneos |
| Astrazeneca Pharmaceuticals LP | $606.06 | 2019-2024 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $583.16 | 2019-2024 | Auryxia, Vafseo |
| Fresenius USA Marketing, INC. | $522.75 | 2020-2025 | Velphoro, Velphoro, Korsuva |
| Calliditas Therapeutics US INC. | $508.95 | 2022-2025 | Tarpeyo |
| Daiichi Sankyo INC. | $308.52 | 2019-2023 | Injectafer |
| Ani Pharmaceuticals, INC. | $284.93 | 2022-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $255.59 | 2020-2024 | Acthar |
| Alexion Pharmaceuticals, INC. | $154.14 | 2022-2024 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $135.90 | 2019-2025 | Jynarque, Rexulti |
| Novartis Pharmaceuticals Corporation | $134.67 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $81.51 | 2021-2023 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $72.05 | 2021-2024 | |
| Travere Therapeutics, INC. | $68.52 | 2022-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $59.10 | 2021-2023 | |
| Novo Nordisk INC | $54.31 | 2024-2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $53.25 | 2024-2025 | Jardiance |
| Mallinckrodt Enterprises LLC | $48.29 | 2019 | |
| Janssen Pharmaceuticals, INC | $42.53 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $40.45 | 2024-2025 | |
| Philips North America LLC | $39.47 | 2019 | |
| Shire North American Group INC | $28.52 | 2019 | |
| Corcept Therapeutics | $24.29 | 2025 | Korlym |
| Ardelyx, INC. | $22.53 | 2024 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.52 | 2025 | Jardiance |
| Acadia Pharmaceuticals INC | $20.27 | 2021 | |
| Cormedix INC. | $20.15 | 2024 | Defencath |
| Apellis Pharmaceuticals, INC. | $16.61 | 2025 | |
| Opko Pharmaceuticals, LLC | $12.63 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Federico Del Toro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.